SM
ABCL icon

SG3 Management’s AbCellera Biologics ABCL Stock Holding History

SG3 Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-43,100
Closed -$420K – 391
2022
Q1 		$420K Buy
+43,100
New +$408K 0.01% 643

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

SG3 Management's ABCL Position: Q2 2022 in Review

SG3 Management sold out of AbCellera Biologics (ABCL) in Q2 2022, closing a stake of 5,000 shares — an estimated $49K sold.

SG3 Management first reported a position in ABCL in Q1 2022 and held it in 1 quarter. The position peaked at $49K in Q1 2022. 161 funds tracked by Wall St. Rank hold ABCL as of Q2 2022.

  • SG3 Management reported no remaining AbCellera Biologics position as of Q2 2022 after selling out during the quarter.
  • SG3 Management sold 5,000 AbCellera Biologics shares in Q2 2022, an estimated $49K.
  • SG3 Management first reported a position in AbCellera Biologics in Q1 2022 and held it in 1 quarter.
  • SG3 Management's AbCellera Biologics position peaked at $49K in Q1 2022.
  • 161 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.